Peelen T, Cornelis R S, van Vliet M, Petrij-Bosch A, Cleton-Jansen A M, Meijers-Heijboer H, Klijn J G, Vasen H F, Cornelisse C J, Devilee P
Department of Human Genetics, University of Leiden, The Netherlands.
Eur J Hum Genet. 1996;4(4):225-30. doi: 10.1159/000472203.
We have analyzed, by a combination of mutation and linkage analysis, the genetic basis of 22 breast cancer families in which at least 4 cases of either breast cancer diagnosed under the age of 60 or ovarian cancer had occurred. Chain-terminating mutations in BRCA1 were evidenced in 6 families, and posterior probabilities of > 0.90 of being linked to BRCA1 in 3. The breast versus ovarian cancer ratio in these 9 families was approximately 2:1. Among the remaining 13 families, significant linkage to markers flanking BRCA2 was established in the admixture test with a maximum multipoint lod score of 3.38, but there was no statistical evidence for genetic heterogeneity. The breast:ovarian cancer ratio in these families was 7:1, suggesting BRCA2 confers a much lower risk for ovarian cancer than does BRCA1. These results suggest that BRCA2 will explain a significant proportion of hereditary breast cancer in the Netherlands, and, together with BRCA1, account for the majority of all high-risk families.
我们通过突变分析和连锁分析相结合的方法,对22个乳腺癌家族的遗传基础进行了分析,这些家族中至少有4例在60岁之前被诊断出患有乳腺癌或卵巢癌。在6个家族中发现了BRCA1基因的链终止突变,在3个家族中发现与BRCA1连锁的后验概率>0.90。这9个家族中乳腺癌与卵巢癌的比例约为2:1。在其余13个家族中,在混合试验中与BRCA2侧翼标记建立了显著连锁,最大多点lod分数为3.38,但没有遗传异质性的统计学证据。这些家族中乳腺癌与卵巢癌的比例为7:1,表明BRCA2赋予卵巢癌的风险比BRCA1低得多。这些结果表明,BRCA2将解释荷兰相当一部分遗传性乳腺癌,并且与BRCA1一起,占所有高危家族的大多数。